ArticleBritish journal of cancer2026

Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004).

Roberto Estay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.